📊 BVS Key Takeaways
Investment Thesis
Bioventus demonstrates solid operational fundamentals with strong profitability (68.3% gross margin) and healthy free cash flow generation ($72.1M), but faces headwinds from flat revenue growth (-0.9% YoY) and declining net income (-16.7% YoY) despite EPS improvement. The company maintains adequate liquidity (1.70x current ratio) but carries significant leverage (1.52x debt/equity) that warrants monitoring.
BVS Strengths
- Exceptional gross margin of 68.3% indicates strong pricing power and operational efficiency in medical device manufacturing
- Robust free cash flow of $72.1M (12.7% FCF margin) with minimal capital intensity provides flexibility for debt reduction or shareholder returns
- Solid liquidity position with 1.70x current ratio and $51.2M cash balance supports operational resilience
BVS Risks
- Revenue stagnation at -0.9% YoY growth suggests market saturation, competitive pressure, or execution challenges in core business
- Net income declined 16.7% YoY despite flat revenues, indicating margin compression and rising operational costs or non-operating expenses
- Elevated debt-to-equity ratio of 1.52x with $279.0M long-term debt creates financial leverage risk and limits strategic flexibility
Key Metrics to Watch
- Revenue growth trajectory - need to see return to positive growth to validate business model sustainability
- Operating margin trends - monitor if cost structure can stabilize at 9.5% level or if further pressure is coming
- Debt reduction pace - track whether $72.1M annual FCF is being allocated to deleverage or if leverage ratios worsen
BVS Financial Metrics
💡 AI Analyst Insight
Bioventus Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BVS Profitability Ratios
BVS vs Healthcare Sector
How Bioventus Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BVS Balance Sheet & Liquidity
BVS 5-Year Financial Trend
5-Year Trend Summary: Bioventus Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.49 indicates the company is currently unprofitable.
BVS Growth Metrics (YoY)
BVS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $138.7M | $3.2M | $0.05 |
| Q2 2025 | $147.7M | $4.8M | $0.07 |
| Q1 2025 | $123.9M | -$2.6M | $-0.04 |
| Q3 2024 | $120.8M | -$4.8M | $-0.07 |
| Q2 2024 | $137.1M | -$3.7M | $-0.06 |
| Q1 2024 | $119.1M | -$4.6M | $-0.07 |
| Q3 2023 | $120.8M | -$7.3M | $-0.12 |
| Q2 2023 | $137.1M | -$3.7M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BVS Capital Allocation
BVS SEC Filings
Access official SEC EDGAR filings for Bioventus Inc. (CIK: 0001665988)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773781416.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773781348.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773781286.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773781219.xml | View → |
| Mar 13, 2026 | 4 | xslF345X05/wk-form4_1773437199.xml | View → |
❓ Frequently Asked Questions about BVS
What is the AI rating for BVS?
Bioventus Inc. (BVS) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BVS's key strengths?
Exceptional gross margin of 68.3% indicates strong pricing power and operational efficiency in medical device manufacturing. Robust free cash flow of $72.1M (12.7% FCF margin) with minimal capital intensity provides flexibility for debt reduction or shareholder returns.
What are the risks of investing in BVS?
Revenue stagnation at -0.9% YoY growth suggests market saturation, competitive pressure, or execution challenges in core business. Net income declined 16.7% YoY despite flat revenues, indicating margin compression and rising operational costs or non-operating expenses.
What is BVS's revenue and growth?
Bioventus Inc. reported revenue of $568.1M.
Does BVS pay dividends?
Bioventus Inc. does not currently pay dividends.
Where can I find BVS SEC filings?
Official SEC filings for Bioventus Inc. (CIK: 0001665988) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BVS's EPS?
Bioventus Inc. has a diluted EPS of $0.33.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.